- Home
- MBRX vs SCNX Comparison
MBRX vs SCNX Comparison
Compare MBRX & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- SCNX
- Stock Information
- Founded
- MBRX 2015
- SCNX 2010
- Country
- MBRX United States
- SCNX United States
- Employees
- MBRX N/A
- SCNX N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- MBRX Health Care
- SCNX Health Care
- Exchange
- MBRX Nasdaq
- SCNX Nasdaq
- Market Cap
- MBRX 24.3M
- SCNX 21.2M
- IPO Year
- MBRX 2016
- SCNX 2020
- Fundamental
- Price
- MBRX $0.48
- SCNX $0.82
- Analyst Decision
- MBRX Strong Buy
- SCNX
- Analyst Count
- MBRX 4
- SCNX 0
- Target Price
- MBRX $5.00
- SCNX N/A
- AVG Volume (30 Days)
- MBRX 3.0M
- SCNX 433.1K
- Earning Date
- MBRX 11-07-2025
- SCNX 11-05-2025
- Dividend Yield
- MBRX N/A
- SCNX N/A
- EPS Growth
- MBRX N/A
- SCNX N/A
- EPS
- MBRX N/A
- SCNX N/A
- Revenue
- MBRX N/A
- SCNX $128,202.00
- Revenue This Year
- MBRX N/A
- SCNX N/A
- Revenue Next Year
- MBRX N/A
- SCNX N/A
- P/E Ratio
- MBRX N/A
- SCNX N/A
- Revenue Growth
- MBRX N/A
- SCNX N/A
- 52 Week Low
- MBRX $0.25
- SCNX $0.69
- 52 Week High
- MBRX $3.65
- SCNX $9.55
- Technical
- Relative Strength Index (RSI)
- MBRX 55.74
- SCNX 31.40
- Support Level
- MBRX $0.39
- SCNX $0.84
- Resistance Level
- MBRX $0.51
- SCNX $0.93
- Average True Range (ATR)
- MBRX 0.03
- SCNX 0.08
- MACD
- MBRX 0.02
- SCNX 0.02
- Stochastic Oscillator
- MBRX 84.47
- SCNX 4.06
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.